TuHURA Biosciences, Inc./NV
For the period ended Mar 31, 2025. Filed May 15, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 15, 2025
HURA$1.51-9.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed consolidated statements of stockholders’ equity
Conde nsed Consolidated Statements of Stockholders’ Equity (Deficit)
| Total | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Additional · Accumulated · Stockholders' | ||||||||||||
| Preferred Stock · Common Stock · Paid in · Due from · Equity · Equity | ||||||||||||
| Shares · Dollars · Shares · Dollars · Capital · Stockholders · (Deficit) · (Deficit) | ||||||||||||
| Balances at January 1, 2024 | 80,561,229 | $8,056 | 68,013,861 | $6,801 | $86,901,394 | $ | - | $(88,474,997) | $(1,558,746) | |||
| Retroactive application of reverse recapitalization | (63,648,386) | $8,857 | (55,846,182) | $5,367 | $(14,224) | $ | - | $ | - | $ | - | |
| Preferred stock (Series A ratio of 1.188, Series A-1 ratio of 1.132, and Series B ratio of 1.191) converted into common stock and multiplied by exchange ratio of 0.1789 | - | |||||||||||
| Recast balances, beginning of period (applying exchange ratio to preferred and common) | 16,912,843 | $16,913 | 12,167,679 | $12,168 | $86,887,170 | $ | - | $(88,474,997) | $(1,558,746) | |||
| Issuance of common shares for asset acquisition | - | - | - | - | - | - | - | - | ||||
| Stock options exercised, cashless | - | - | 10,842 | 10 | (10) | - | - | - | ||||
| Stock compensation expense | - | - | - | - | 334,604 | - | - | 334,604 | ||||
| Net loss | - | - | - | - | - | - | (4,842,142) | (4,842,142) | ||||
| Balances at March 31, 2024 | 16,912,843 | $16,913 | 12,178,521 | $12,178 | $87,221,764 | $ | - | $(93,317,139) | $(6,066,284) | |||
| Total | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Additional · Accumulated · Stockholders' | |||||||||
| Preferred Stock · Common Stock · Paid in · Due from · Equity · Equity | |||||||||
| Shares · Dollars · Shares · Dollars · Capital · Stockholders · (Deficit) · (Deficit) | |||||||||
| Balances at January 1, 2025 | 278,530 | $278,530 | 42,323,759 | $42,324 | $125,397,691 | $ | - | $(111,124,569) | $14,593,976 |
| Issuance of common shares for warrants exercised | - | - | 1,208,104 | 1,208 | 3,560,907 | (3,057,904) | - | 504,211 | |
| Stock options exercised, cashless | - | - | 148,533 | 148 | (148) | - | - | - | |
| Stock compensation expense | - | - | - | - | 1,424,736 | - | - | 1,424,736 | |
| Series A Preferred Stock cash dividend | - | - | - | - | - | - | (2,089) | (2,089) | |
| Net loss | - | - | - | - | - | - | (6,664,371) | (6,664,371) | |
| Balances at March 31, 2025 | 278,530 | $278,530 | 43,680,396 | $43,680 | $130,383,186 | $(3,057,904) | $(117,791,029) | $9,856,463 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.